|
2-CHLORO-N-[(1R,2R)-1-HYDROXY-2,3-DIHYDRO-1H-INDEN-2-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE
|
DB06986 |
|
|
Ovalicin
|
DB04324 |
|
|
2-[({4-[2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)amino]benzoic acid
|
DB06985 |
|
|
IRX-5183
|
DB05653 |
|
|
N-Hexylphosphonate Ethyl Ester
|
DB04321 |
|
|
(1R,2R,3R,4S,5R)-4-(BENZYLAMINO)-5-(METHYLTHIO)CYCLOPENTANE-1,2,3-TRIOL
|
DB06984 |
|
|
LY249543
|
DB04322 |
|
|
VTP-201227
|
DB05652 |
[VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications. It is being developed by Vitae Pharmaceuticals.] |
|
(5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol
|
DB06983 |
|
|
(2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine
|
DB06959 |
|
|
5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
|
DB06958 |
|
|
Retaspimycin
|
DB05626 |
|
|
4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
|
DB06957 |
|
|
CTCE-9908
|
DB05625 |
|
|
N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
|
DB06956 |
|
|
Teverelix
|
DB05624 |
[A synthetic decapeptide, water-soluble Gonadotropin-releasing hormone antagonist. It has reached phase II clinical trials.] |
|
3,4-bis(7-chloro-1H-indol-3-yl)-1H-pyrrole-2,5-dicarboxylic acid
|
DB06955 |
|
|
2-(cycloheptylmethyl)-1,1-dioxido-1-benzothiophen-6-yl sulfamate
|
DB06954 |
|
|
2-CHLORO-5-(3-CHLORO-PHENYL)-6-[(4-CYANO-PHENYL)-(3-METHYL-3H-IMIDAZOL-4-YL)- METHOXYMETHYL]-NICOTINONITRILE
|
DB06953 |
|
|
(2S)-2-HYDROXY-2H-CHROMENE-2-CARBOXYLIC ACID
|
DB06952 |
|
